Anika Therapeutics, Inc. (NASDAQ: ANIK) reported Q3 EPS of $0.40, $0.07 better than the analyst estimate of $0.33. Revenue for the quarter came in at $22.1 million versus the consensus estimate of $20.33 million.

For earnings history and earnings-related data on Anika Therapeutics, Inc. (ANIK) click here.